Intervenn Biosciences was co-founded by faculty members at Stanford University and University of California, Berkeley.
Intervenn Biosciences, a US-based precision medicine technology developer co-founded by Stanford University and University of California, Berkeley faculty, has closed a $201m series C round.
The round was co-led by telecoms firm SoftBank, health system Heritage Provider Network, Irving Investors and Highside Capital Management. It was filled out by Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures.
Intervenn Biosciences has developed an artificial intelligence-equipped glycoproteomics platform and a liquid biopsy assay for immune checkpoint inhibitor response prediction.…
